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Abstract
Background: Aberrant platelet derived growth factor (PDGF) signaling has been associated with prostate cancer (PCa)
progression. However, its role in the regulation of PCa cell growth and survival has not been well characterized.
Methodology/Principal Findings: Using experimental models that closely mimic clinical pathophysiology of PCa
progression, we demonstrated that PDGF is a survival factor in PCa cells through upregulation of myeloid cell leukemia-
1 (Mcl-1). PDGF treatment induced rapid nuclear translocation of b-catenin, presumably mediated by c-Abl and p68
signaling. Intriguingly, PDGF promoted formation of a nuclear transcriptional complex consisting of b-catenin and hypoxia-
inducible factor (HIF)-1a, and its binding to Mcl-1 promoter. Deletion of a putative hypoxia response element (HRE) within
the Mcl-1 promoter attenuated PDGF effects on Mcl-1 expression. Blockade of PDGF receptor (PDGFR) signaling with a
pharmacological inhibitor AG-17 abrogated PDGF induction of Mcl-1, and induced apoptosis in metastatic PCa cells.
Conclusions/Significance: Our study elucidated a crucial survival mechanism in PCa cells, indicating that interruption of the
PDGF-Mcl-1 survival signal may provide a novel strategy for treating PCa metastasis.
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Introduction
The platelet-derived growth factors (PDGF) family consists of
five dimeric isoforms: PDGF-AA, -AB, -BB, -CC and -DD [1],
which exert their cellular effects through two structurally similar
tyrosine kinase receptors (PDGFR-a and -b) expressed by many
different cell types [2]. Ligand binding to PDGFRs results in the
dimerization and autophosphorylation of the receptor kinases,
subsequently recruiting certain Src homology 2 (SH2) domain-
containing adaptor proteins (e.g., Src, Grb2 and Shc) to specific
phosphorylated tyrosine residues. Several signaling cascades,
including Ras-mitogen-activated protein kinase (MAPK), phos-
pholipase-c and phos-phatidyl-inositol-39-kinase (PI3K)/Akt, have
been characterized as the major downstream pathways mediating
PDGF functions [3]. Other adaptor molecules (e.g., the Fer and
Fes tyrosine kinase family) and transcriptional factors (e.g., b-
catenin) are also involved in PDGF signaling in certain cell types
[4,5,6,7,8].
Aberrant PDGFexpression has been frequently associated with the
neoplastic component of human tumors, whereas PDGFRs are
mainly found in the fibroblastic and vascular tumor stroma
[9,10,11,12,13]. These observations suggested that tumor-derived
PDGF may primarily act as a paracrine signaling molecule in solid
tumors. Supporting this concept, recent studies have demonstrated
that PDGF is a potent pro-angiogenic factor by promoting the
recruitment and growth of stromal fibroblasts, perivascular cells and
endothelialcells,therebyindirectlyaffectingtumorgrowth,metastatic
dissemination and drug resistance [2,3,14,15,16]. Interestingly,
emerging evidence indicated that PDGF autocrine signaling may
also play an important role during tumor progression. Mutational
activation or co-expression of PDGF ligands and receptors are
capable of stimulating tumor cell growth and proliferation in several
nonepithelial malignancies, including glioblastomas and osteosarco-
ma [17]. More recently, autocrine PDGF signaling has been
associated with epithelial-to-mesenchymal transition (EMT) in
carcinoma cells from the breast, colon, prostate and liver, suggesting
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30764a causative role of autocrine PDGF signaling in metastasis [7,8,18,19].
Nonetheless, despite the well-established correlation between deregu-
lated paracrine PDGF signaling and tumor progression, the functions
and mechanisms of autocrine PDGF signaling in epithelial cancer cells
remain elusive [3,17].
Acquisition of apoptosis resistance is characteristic of metastatic
tumor cells, which may confer survival advantages during
invasion, metastasis and colonization [20]. We recently correlated
overexpression of myeloid cell leukemia-1 (Mcl-1), a member of
the Bcl-2 family, with the progression of prostate cancer (PCa)
towards bone metastasis [21]. In this study, we provide evidence
that PDGF-BB is a survival factor in metastatic PCa cells by
upregulating Mcl-1 expression through a signaling mechanism
mediated by the transcriptional factors b-catenin and hypoxia-
inducible factor (HIF)-1a.
Materials and Methods
Cell Culture
Human PCa cell lines ARCaPE, ARCaPM [22], LNCaP
(American Type Culture Collection, ATCC, Manassas, VA), C4-
2 [23] and PC3 (ATCC) were routinely maintained in T-medium
(Invitrogen, Carlsbad, CA) with 5% fetal bovine serum (FBS). For
the treatments with PDGF isoforms, PCa cells seeded in 96-well
plates (3,000 cell/well) were serum-starved overnight, replaced with
fresh serum-free T-medium, and incubated in the presence of
varying concentrations of recombinant human PDGF-AA, -AB, -
BB (R&DSystems, Minneapolis, MN), or phosphate-buffered saline
(PBS) for indicated times. Recombinant human interleukin-6 (IL-6)
was purchased from R&D Systems. For chemotherapy drug
treatment, docetaxel (Sanofi Aventis, Bridgewater, NJ) or dimethyl
sulfoxide(DMSO;Sigma-Aldrich,St.Louis,MO)wasaddedtocells
and incubated for 72 h. Cell proliferation was measured using the
CellTiter 96AQ proliferation assayaccordingtothemanufacturer’s
instructions (Promega, Madison, WI). Viable cells were counted in
triplicate using a hemacytometer and trypan blue staining.
Plasmids and small interfering RNAs (siRNAs)
The full-length human Mcl-1 promoter region cloned into a
firefly luciferase reporter vector pGL3-Basic (Promega, Madison,
WI) was kindly provided by Dr. Steven W. Edwards (University of
Liverpool, Liverpool, UK) [24]. The hypoxia-responsive element
(HRE) (fragment 2900 to 2884)-truncated construct was
obtained by digestion of the full-length promoter using KpnI
(from position 23914 to 2855) and then ligated using T4 DNA
ligase (New England Biolabs, Ipswich, MA). Both plasmid
constructs were confirmed by sequence analysis. The pHIF1-luc
reporter was purchased from Panomics (Fremont, CA). TOPFlash
and FOPFlash T-cell factor (TCF) reporters were obtained from
Upstate (Billerica, MA). pTK-RL plasmid was purchased from
Promega. Human Mcl-1 expression vector (pCMV-Mcl-1) was
obtained from Origene, Inc. Human b-catenin expression plasmid
was provided by Dr. Zhi-Ren Liu. ON-TARGETplus SMART-
pool siRNAs against b-catenin, p68, PDGFR-a and PDGFR-b,
and control siRNA were obtained from Dharmacon, Inc (Chicago,
IL). HIF-1a and control siRNA were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Transient transfection of
DNA constructs and siRNAs was performed using Lipofectamine
2000 or Oligofectamine reagents (Invitrogen), according to the
manufacturer’s protocols and our published procedures [21,25].
Western Blot Analysis
Total cell lysates were prepared using radioimmunoprecipita-
tion (RIPA) buffer (Santa Cruz Biotechnology, Inc.). Nuclear
proteins were extracted using a Novagen kit (EMD Biosciences,
San Diego, CA). Immunoblotting analysis followed standard
procedures [25]. ImageJ software (National Institutes of Health)
was used to quantitate the relative protein expression as
normalized to the loading controls. Information for the antibodies
used in this study was described in Supplemental Table S1.
Immunoprecipitation
The Immunoprecipitation Starter Pack (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ) was used according to the
manufacturer’s instructions. Total nuclear lysates (1 mg) were
immunoprecipitated with 5 mg rabbit anti-HIF-1a antibody,
mouse anti-b-catenin antibody, mouse anti-c-Abl and rabbit
anti-p68 antibody (Supplemental Information, Table S1), or
normal IgG (R&D Systems). Protein A/G Sepharose 4 Fast Flow
beads were added to precipitate proteins, then washed and eluted.
The samples were further processed for Western blot analysis.
Immunofluorescence and Confocal Imaging
Immunofluorescence was performed as described previously
[21] using mouse anti-b-catenin, rabbit anti-p68 and anti-HIF-1a
antibodies (Supplemental Table S1). Either Alexa 488 or 555
secondary antibodies (Invitrogen) were used at a dilution of 1:500
and were incubated for 1 h at room temperature. Nuclear staining
was performed by incubating cells with 0.4 mmol/L 49,6-
diamidino-2-phenylindole (DAPI) to mounting slides. Cells were
imaged on a Zeiss LSM 510 META. In all cases, either a 63x or
100x Zeiss Plan-Apo oil objective was used (numerical aperture of
1.3 and 1.4, respectively). All images had contrast expansion
performed in Adobe Photoshop.
Quantitative RT-PCR (qRT-PCR) and RT-PCR
Total RNA was prepared with Qiagen RNeasy Kit (Valencia,
CA). The first-strand cDNA was synthesized using SuperScript
HIII First-Strand Synthesis System (Invitrogen). Quantitative PCR
was performed by the LightCycler 480 system (Roche Applied
Science) using a BrilliantH SYBRH Green QPCR Master Mix
(Stratagene) according to the manufacturer’s instructions. For end-
point RT-PCR, the SuperScriptH III One-Step RT-PCR kit
(Invitrogen) was used following the manufacturer’s protocol. The
specific primer pairs are described in Supplemental Table S2.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
was amplified with a pair of primers described previously [25]
and used to normalize RNA inputs.
Chromatin Immunoprecipitation Assay (ChIP)
The sequential ChIP (ChIP-re-ChIP) experiment was per-
formed using the Active Motif Re-ChIP-ITH kit (Active Motif,
Carlsbad, CA). Briefly, PCa cells were serum-starved overnight
and replaced with fresh serum-free medium, incubated with
PDGF-BB or PBS for indicated times. Cells were fixed 10 min at
room temperature by 1% formaldehyde solution to cross-link
DNA-protein interactions. Chromatin was sheared for 8 min using
a ChIP-IT Express Enzymatic Shearing kit (Active Motif) [25]. A
portion of chromatin was reversed and used as input DNA. For
immunoprecipitation, 2 mg of anti-b-catenin antibody were added
and incubated overnight, with normal IgG as the control
(Supplemental Table S1). Eluted chromatin was desalted, and an
aliquot was used as control for the first ChIP reaction. The re-
ChIP reaction was then performed with 2 mg of anti-HIF-1a
antibody or with IgG control. PCR primers for the HRE region in
human Mcl-1 promoter were described in the Supplemental Table
S2. PCR reactions were performed for 40 cycles, with primer
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Master Mix kit (Invitrogen).
Statistical Analysis
All data represent three or more experiments. Errors are S.E.
values of averaged results. For each assay Student’s t-test was used
for statistical comparison with the control groups. Values of
p#0.05 were taken as a significant difference between means.
Statistical analysis was performed using the Sigmaplot software
11.0 (Systat Software, Inc., Chicago, IL).
Results
Mcl-1 is a survival factor in PCa cells
Previously we demonstrated that Mcl-1 overexpression is
associated with in vivo bone metastatic propensity of human PCa
cells, and importantly, correlated with clinical PCa bone metastasis
[21]. Consistently, using a human PCa ARCaP cellular model that
could closely mimic the pathophysiology of bone metastasis in
immunocompromised mice [26], we found that Mcl-1 expression
was significantly increased in highly bone metastatic ARCaPM
cells when compared to that in the low-invasive counterpart
ARCaPE cells (Figure 1A). We hypothesized that upregulation of
Mcl-1 may confer metastatic PCa cells survival advantages,
allowing them to escape apoptotic fate during invasion and
dissemination and successfully establish distant metastasis [20].
Supporting this notion, ectopic expression of Mcl-1 enhanced PCa
cell resistance to docetaxel (Figure 1B), a commonly used
chemotherapeutic drug in hormone-refractory and metastatic
PCa [27]. These results indicated that upregulation of Mcl-1 may
account for, at least in part, resistance to apoptosis in metastatic
PCa cells.
PDGF-BB induces Mcl-1 expression and antagonizes
apoptosis in PCa cells
Intriguingly, PDGF-BB was found to significantly induce Mcl-1
expression in PCa cells (Figure 1C, Supplemental Figure S1).
Treatment with recombinant human PDGF-BB increased Mcl-1
mRNA in a dose- and time-dependent manner, though the
optimal conditions for the maximum accumulation of Mcl-1
mRNA varied in different PCa cell lines. Western blot analysis
confirmed the inductive effects of PDGF-BB on Mcl-1 expression
at protein level. These data identified PDGF-BB as a novel
regulator of Mcl-1 expression, which could provide a survival
mechanism to protect PCa cells from apoptosis. Indeed, addition
of PDGF-BB in PCa cell cultures effectively antagonized the
cytotoxicity of docetaxel over a wide range of doses (Figure 1D).
Expression profile of PDGF autocrine signaling
components in PCa cells
We examined the expression pattern of PDGFs and their
receptors in PCa cells (Figure 2A). RT-PCR analyses showed that
the PDGF isoforms were differentially expressed at mRNA level,
and among them, increased PDGF-B and PDGF-D were observed
in C4-2 and ARCaPM cells when compared to the parental
LNCaP and ARCaPE cells, respectively. Consistent with previous
studies [19], PC3 cells were found to express high levels of PDGF-
D, PDGFR-a and -b. Interestingly, PDGFR-a mRNAs appeared
to be substantially expressed in PCa cells, which was confirmed at
protein level by Western blot analysis. In contrary, though
PDGFR-b mRNAs were detected by RT-PCR in most PCa cell
lines, immunoblotting analysis could only confirm protein
expression in ARCaPE and ARCaPM cells (Figure 2A, right
panel). Taken together, these data suggested a functional PDGF
autocrine signaling in certain PCa cells.
An autocrine PDGFR signaling mediates PDGF-BB
regulation of Mcl-1 in PCa cells
Both PDGFR-a and -b were highly expressed in bone
metastatic ARCaPM cells, and rapidly phosphorylated in a time-
dependent manner in response to the stimulation of exogenous
PDGF-BB (Figure 2B). Interesting, depletion of either PDGFR-a
or -b by isoform-specific siRNA did not block the inductive effect
of PDGF-BB on Mcl-1 expression (Figure 2C, left and central
panels), suggesting that activation of either receptors may be
sufficient for the upregulation of Mcl-1. Supporting this hypoth-
esis, transient transfection with a mixture of siRNAs targeting both
PDGFR-a and -b inhibited the basal expression of Mcl-1, and
abrogated PDGF-BB induction of Mcl-1 ARCaPM cells
(Figure 2C, right panel). Alternatively, treatment with AG-17
(Tyrphostin), a selective pharmacological inhibitor of PDGFRs
[28], reduced Mcl-1 expression at both mRNA and protein levels
and markably increased cleavage of poly-ADP ribose polymerase
(PARP), an indicator of apoptosis. These effects were attenuated
by the presence of PDGF-BB in cultures (Figure 2D). Consistently,
AG-17 treatment at low doses (such as 100 nM) effectively induced
apoptosis in ARCaPE and ARCaPM cells (Figure 2E), indicating a
pivotal role of PDGFR signaling in the survival of PCa cells.
b-catenin mediates PDGF regulation of Mcl-1 expression
in PCa cells
Activation of the b-catenin pathway is a downstream event of
PDGF signaling in certain epithelial cancer cells [7,8,29]. Western
blot analysis found that b-catenin and TCF4, a major b-catenin-
interacting transcription factor [30], were differentially expressed
in PCa cells (Figure 3A), suggesting a functional b-catenin-TCF4
signaling in these cells. In fact, an artificial TCF promoter was
activated in both the LNCaP-C4-2 and ARCaPE-ARCaPM cell
lineages, and the reporter activities appeared to be associated with
increased in vivo metastatic potential in C4-2 and ARCaPM cells
(Figure 3B). It is worth noting that both b-catenin and TCF4 were
substantially presented in the nucleus of ARCaPE and ARCaPM
cells (Figure 3A, low panel), which exhibited markedly higher basal
TCF activities than either LNCaP or C4-2 cells (by ,100-fold)
(Figure 3B).
Upon PDGF-BB treatment, the nuclear presence of b-catenin
was rapidly increased in ARCaPM cells (Figure 3C, upper panel).
Consistently, TCF reporter activity was also significantly increased
following PDGF-BB stimulation, which was attenuated by the pre-
treatment with AG-17 (Figure 3C, bottom panel). These data
indicated that PDGF-BB activated b-catenin signaling in a
PDGFR-dependent manner.
To investigate the role of b-catenin in the regulation of Mcl-1
expression, ARCaPM cells were transiently transfected with a
construct expressing wild-type b-catenin. RT-PCR and Western
blot analyses showed that ectopic epression of b-catenin
increseased Mcl-1 at both mRNA and protein levels (Figure 3D).
In contrary, b-catenin depletion using a siRNA pool efficiently
inhibited both the basal expression of Mcl-1 and its induction by
PDGF-BB (Figure 3E). Consistently, whereas PDGF-BB signifi-
cantly induced the luciferase activity of a full-length human Mcl-1
promoter in ARCaPM cells transfected with non-targeting control
siRNAs, this effect was abrogated by transient depletion of
endogeneous b-catenin (Figure 3F). These results suggested that
activation of b-catenin signaling may be sufficient and required for
Mcl-1 expression in PCa cells.
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30764Figure 1. PDGF-BB upregulates Mcl-1 and protects PCa cells from apoptosis. (A) Mcl-1 protein expression in the lineage-related ARCaPE and
ARCaPM cells. (B) Ectopic expression of Mcl-1 in ARCaPM cells and the effects on docetaxel cytotoxicity in ARCaPM cells. pCMV: vector control. (C) Left
panel: The dose- and time-dependent effects of PDGF-BB on Mcl-1 mRNA expression in ARCaPM cells; middle panel: qRT-PCR analysis of Mcl-1 mRNA
expression in response to PDGF-BB treatment in ARCaPM cells (24 h); right panel: The effects of PDGF-BB treatment (20ng/ml, 72 h) on Mcl-1 protein
expression in ARCaPM cells. ImageJ was used to quantitate the relative expression of Mcl-1 protein. (D) The effects of exogenous PDGF-BB on the
cytotoxicity of docetaxel in ARCaPM cells, as determined by the MTS assay.
doi:10.1371/journal.pone.0030764.g001
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We investigated whether a c-Abl-p68-dependent pathway is
involved in the PDGF activation of b-catenin signaling in PCa
cells [7]. Western blot analyses found that c-Abl and p68 were
differentially expressed in PCa cells (Figure 4A). Upon PDGF-BB
treatment, tyrosine phosphorylation of c-Abl and p68 were rapidly
activated, as evidenced by immunoprecipitation-immunoblotting
assays (Figure 4B, left and middle panels). Importantly, the
presence of b-catenin in p68 immunoprecipitates was also
increased in a time-dependent manner, suggesting an enhanced
physical association between b-catenin and p68 proteins
(Figure 4B, middle panel), which was further confirmed by a
reciprocal immunoprecipitation experiment (Figure 4B, right
panel). In fact, PDGF-BB induced rapid nuclear translocation of
p68 within 30 min (Figure 4C), which was associated with
increased co-localization of p68 and b-catenin in the nucleus
(Figure 4D). These data indicated that PDGF-BB could activate
the c-Abl-p68 cascade and subsequent b-catenin signaling in PCa
cells.
To examine whether p68 is required for the regulation of Mcl-1
expression, ARCaPM cells were transfected with p68 siRNA or
control siRNA, and analyzed for the expression of Mcl-1 at the
mRNA and protein levels. As shown in Figure 4E, depletion of
p68 inhibited endogeneous b-catenin and effectively attenuated
PDGF-BB induction of Mcl-1 expression. Consistently, Mcl-1
promoter activity was significantly inhibited by the treatment with
p68 siRNA in ARCaPM cells, either with or without the presence
of PDGF-BB in the cultures (Figure 4F). These data indicated an
indispensible function of p68 in the regulation of Mcl-1 in PCa
cells.
PDGF-BB promotes protein interaction between
b-catenin and HIF-1a in PCa cells
Our previous studies demonstrated an important role of HIF-1a
in bone metastatic PCa cells [25]. Interestingly, transfection of a
HIF-1a-specific siRNA significantly reduced Mcl-1 protein
expression in ARCaPM cells (Figure 5A), suggesting that HIF-1a
may be required for Mcl-1 regulation in PCa cells. To examine
Figure 2. Activation of the PDGFR signaling is required for Mcl-1 expression in PCa cells. (A) Expression profile of PDGFR signaling
components in PCa cells, as analyzed by RT-PCR and Western blotting. (B) The effects of PDGF-BB (20 ng/ml) on the phosphorylation of PDGFR-a and
-b in ARCaPM cells. (C) The effects of depleting PDGFR-a or/and -b on Mcl-1 protein expression in ARCaPM cells. The cells were transfected with either
isotype-specific siRNAs targeting PDGFR-a (left panel, 30 nM) or PDGFR- b (central panel, 100 nM), or a mixture of PDGFR-a and -b siRNAs (right panel)
for 48 h, serum-starved overnight, and incubated in the presence or absence of PDGF-BB (20 ng/ml) for 72 h. (D) Upper panel: The time-dependent
effects of AG-17 (100 nM) on Mcl-1 mRNA expression in ARCaPM cells; bottom panel: The effects of AG-17 treatment on the expression of Mcl-1 and
cleaved PARP in the presence (20 ng/ml) or absence of PDGF-BB (20 ng/ml) in ARCaPM cells. (E) The effects of AG-17 treatment (100 nM, 72 h) on the
viability of ARCaPE and ARCaPM cells.
doi:10.1371/journal.pone.0030764.g002
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HIF-1a and b-catenin, nuclear proteins were prepared from
ARCaPM cells treated with PDGF-BB for varying times. Western
blot analysis found that both HIF-1a and b-catenin were rapidly
increased in the nucleus (Figure 5B). A co-immunoprecipitation
assay showed that in response to PDGF-BB stimulation, nuclear
presence of b-catenin rapidly increased in the HIF-1a immuno-
precipitates (Figure 5C, upper panel). Reciprocal co-immunopre-
cipitation with an anti-b-catenin antibody confirmed an increased
association of nuclear HIF-1a with b-catenin following PDGF-BB
treatment (Figure 5C, bottom panel). The enhanced co-localiza-
tion of b-catenin and HIF-1a proteins was further demonstrated
by confocal microscopy, which appeared to acheive the maximum
intensity at 30 min upon PDGF-BB stimulation (Figure 5D).
These results indicated that in repsonse to PDGF-BB stimulation,
b-catenin physically interacts with HIF-1a in the nucleus, which
may lead to the activation of Mcl-1 transcription in PCa cells.
A putative HRE motif is required for PDGF-BB activation
of Mcl-1 promoter
HIF-1a binds to the HRE cis-elements within the promoters of
hypoxia-responsive genes and regulates their expression [31]. We
examined whether PDGF-BB-induced nuclear accumulation of
HIF-1a was associated with the activation of HRE-dependent
transcription. In ARCaPM cells, PDGF-BB treatment significantly
increased luciferase expression driven by an artificial HRE
promoter (pHIF-luc) (Figure 6A). Interestingly, a putative HRE
motif was identified within human Mcl-1 promoter region, which
is located between -900 and -884 nucleotides at the 59-upstream of
transcription start site [24]. To investigate the potential role of this
cis-element in PDGF regulation of Mcl-1 transcription, we
characterized a deletion mutant of the putative HRE motif using
human Mcl-1 promoter region as the template (Figure 6B). The
resulting reporter construct (p-Mcl-1-Luc: DHRE), or the
luciferase reporter driven by the full-length Mcl-1 promoter (p-
Figure 3. b-catenin mediates PDGF regulation of Mcl-1 expression in PCa cells. (A) Expression profile of b-catenin-TCF signaling
components in PCa cells. (B) TCF reporter activity in the LNCaP-C4-2 and ARCaPE-ARCaPM cells. (C) Upper panel: The effects of PDGF-BB (20 ng/ml) on
the nuclear translocation of b-catenin in ARCaPM cells; Bottom panel: The effects of PDGF-BB (20 ng/ml) on TCF reporter activity in the presence (100
nM) or absence of AG-17. (D) The effects of ectopic expression of b-catenin (72 h) on Mcl-1 expression at both mRNA and protein levels. (E) The
effects of b-catenin depletion on PDGF-BB regulation of Mcl-1 expression in ARCaPM cells. The cells were transfected with b-catenin siRNA or control
siRNA (30 nM) for 48 h, serum-starved overnight, and incubated in the presence or absence of PDGF-BB (20 ng/ml) for 72 h. (F) The effects of b-
catenin depletion on Mcl-1 reporter activity in ARCaPM cells. The cells were transfected with b-catenin or control siRNA (30 nM) for 48 h, and further
transfected with a human Mcl-1 reporter for 24 h. Following serum starvation overnight, the cells were incubated in the presence or absence of
PDGF-BB (20 ng/ml) for 48 h.
doi:10.1371/journal.pone.0030764.g003
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tively, and treated with PDGF-BB or PBS. IL-6, which has been
shown to activate Mcl-1 transcription in PCa and cholangiocarci-
noma cells through a signal transducer and activator of
transcription 3 (Stat3)-dependent mechanism [32,33], was includ-
ed as the positive control. Luciferase activity assay showed that
PDGF-BB induced the activation of p-Mcl-1-Luc promoter to a
greater degree than IL-6 in ARCaPM cells. Significantly, deletion
of the HRE motif not only reduced the basal activity of Mcl-1
promoter, but also abrogated the inductive effects of PDGF-BB on
reporter activity. In contrary, p-Mcl-1-Luc: DHRE, containing a
Stat3-binding sequence at position between 292 and 283 [32],
remained activated upon IL-6 treatment (Figure 6C). A similar
effect of HRE deletion on the differential response of Mcl-1
promoter to PDGF-BB and IL-6 was also observed in C4-2 cells
(Supplemental Figure S2). These data indicated that the putative
HRE cis-element is required for PDGF-BB activation of Mcl-1
expression in PCa cells.
PDGF-BB promotes the binding of both b-catenin and
HIF-1a to Mcl-1 promoter region
We investigated whether PDGF-BB promoted specific binding
of both b-catenin and HIF-1a to Mcl-1 promoter by a sequential
ChIP assay. Fractionated chromatin from controls and PDGF-BB-
treated ARCaPM cells was firstly immunoprecipitated with a b-
catenin antibody, and the precipitates were subjected to a re-ChIP
assay with an HIF-1a antibody. From the isolated DNA, a 151-bp
fragment containing the HRE region on the Mcl-1 promoter could
be amplified from the re-ChIP precipitates. Upon PDGF-BB
stimulation, a considerable increase in the binding of both b-
catenin and HIF-1a to the HRE region was observed (Figure 6D).
These results demonstrated that PDGF-BB could facilitate the
association of Mcl-1 promoter with a transcriptional complex
consisting of b-catenin and HIF-1a in PCa cells.
Discussion
In this study, we uncovered the PDGF-Mcl-1 signaling as a
crucial survival mechanism in PCa cells (Figure 7). For the first
time, we demonstrated that: 1) PDGF-BB is a novel regulator of
Mcl-1 expression; 2) PDGF-BB activation of autocrine PDGFR
signaling promotes the interaction between b-catenin and HIF-1a,
presumably through a c-Abl-p68-dependent mechanism; 3) a
putative HRE motif is required for the basal expression and
PDGF-BB activation of Mcl-1 promoter; and 4) inhibition of the
PDGFR-Mcl-1 signaling using a small-molecule inhibitor AG-17
could activate apoptotic response in metastatic PCa cells. These
results support that targeting PDGF-Mcl-1 pathway may provide a
novel strategy for treating PCa metastasis.
Figure 4. PDGF-BB activates the c-Abl-p68-b-catenin signaling cascade in PCa cells. (A) Expression of c-Abl and p68 in PCa cells. (B) Left
panel: The effects of PDGF-BB (20 ng/ml) on the phosphorylation of c-Abl; middle panel: The effects of PDGF-BB (20 ng/ml) on the phosphorylation of
p68 and the expression of b-catenin in the p68 immunoprecipitates in ARCaPM cells. Phosphorylation of p68 on the tyrosine sites was detected using
a pan-phosphorylated-Tyr antibody; right panel: The effects of PDGF-BB (20 ng/ml) on the expression of p68 in the b-catenin immunoprecipitates in
ARCaPM cells. (C) The effects of PDGF-BB (20 ng/ml) on the nuclear translocation of p68 in ARCaPM cells. (D) Confocal microscopy analysis of the
effects of PDGF-BB on the co-localization of b-catenin and p68 in the nucleus in a time course experiment in ARCaPM cells. (E) The effects of p68
depletion on PDGF regulation of Mcl-1 in ARCaPM cells. The cells were transfected with p68 or control siRNA (30 nM) for 48 h, serum-starved
overnight, and incubated in the presence or absence of PDGF-BB (20 ng/ml) for 24 h (upper panel) or 72 h (bottom panel). Upper panel: RT-PCR
analysis of mRNA expression of p68 and Mcl-1; bottom panel: Western blot analysis of protein expression of p68, b-catenin and Mcl-1. (F) The effects
of p68 depletion on Mcl-1 reporter activity in ARCaPM cells. The cells were transfected with p68 or control siRNA (30 nM) for 48 h, and further
transfected with human Mcl-1 reporter for 24 h. Following serum starvation overnight, the cells were incubated in the presence or absence of PDGF-
BB (20 ng/ml) for 48 h.
doi:10.1371/journal.pone.0030764.g004
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downstream pathways in the regulation of cell growth, prolifer-
ation, migration and survival [3]. In tumor-associated endothelial
and fibroblast stromal cells, PDGF has been shown to activate Akt-
and MAPK-dependent survival mechanisms [34,35,36,37]. Yet, it
remains elusive on the molecular mechanism by which PDGF
exerts its functions in epithelial cancer cells. Recent data have
linked autocrine PDGF signaling to the activation of b-catenin
pathway. For instance, PDGF-AB was found to induce nuclear b-
catenin accumulation via a PI3K-dependent mechanism, thereby
protecting hepatocellular carcinoma cells from anoikis during
metastatic dissemination [8]. In human colon cancer cells, PDGF-
BB induces EMT [7] and upregulates cyclin D1 and c-Myc [38]
by activating b-catenin-dependent gene expression. In both cases,
PDGF-BB induces the phosphorylation of c-Abl kinase, which
subsequently recruits p68, an RNA helicase with ATPase activity,
and activates its phosphorylation. Phosphorylated p68 binds b-
catenin and promotes its nuclear translocation by displacing Axin
from b-catenin and blocking b-catenin degradation, eventually
promoting the interaction of b-catenin with TCF/LEF and the
assembly of transcription complexes [7]. In this study, we provided
molecular evidence demonstrating that in PCa cells that express
high basal levels of p68 and b-catenin, PDGF could significantly
promote physical interaction and rapid nuclear translocation of
p68 and b-catenin. Importantly, p68 depletion in PCa cells led to
the inhibition of Mcl-1 expression and induction of apoptosis, as
evidenced by the appearance of cleaved PARP (Supplemental
Figure S3). These results, for the first time, underscored a critical
role of p68 in the regulation of PCa cell survival. Interestingly, a
recent study demonstrated that p68 is actually a novel coactivator
of androgen receptor (AR) [39], another transcription factor
interacting with b-catenin in certain PCa cells (such as LNCaP and
C4-2) [40]. It would be intriguing to further investigate the
dynamic interaction between p68, b-catenin and AR, and its
biological consequences in these cells. In addition, other pathways
may be involved in the PDGF activation of b-catenin signaling.
For example, PDGF-BB treatment was found to induce rapid
phosphorylation of both Akt and glycogen synthase kinase 3-b
(GSK-3b) (Supplemental Figure S4), which may also contribute to
the elevated intracellular levels and nuclear accumulation of b-
catenin [41].
Our data confirmed a highly active b-catenin/TCF signaling in
ARCaP cells and correlated the TCF reporter activity with the in
vivo metastatic potential (Figure 3A, 3B), indicating these cells
could be used as an excellent model system for investigating b-
catenin signaling in PCa progression [42]. Though PDGF-BB
activated the full-length human Mcl-1 promoter (Figure 3F) in a
similar manner to its effect on the luciferase expression driven by
an artificial TCF-binding motif (pTOPFlash), it appeared that
human Mcl-1 promoter does not contain any consensus sequences
of TCF/lymphoid enhancer-binding factor (LEF). These results
suggested that certain transcription factor(s), other than TCF,
could be responsible for b-catenin activation of Mcl-1 transcrip-
tion. One of such candidates was cAMP-response element-binding
protein (CREB), which has been implicated in the regulation of
Mcl-1 expression through the PI-3K/Akt signaling pathway [43]
and highly expressed in ARCaP cell lineage [25]. Western blotting
analyses, however, could not detect a significant increase in
Figure 5. PDGF-BB promotes protein interaction between b-catenin and HIF-1a in PCa cells. (A) The effects of HIF-1a depletion on Mcl-1
expression in ARCaPM cells. The cells were transfected with HIF-1a or control siRNA (30 nM) for 72 h, and analyzed for Mcl-1 expression by
immunoblotting. (B) Western blot analysis of the effects of PDGF-BB (20 ng/ml) on the nuclear translocation of b-catenin and HIF-1a in ARCaPM cells.
(C) Co-immunoprecipitation assays of the effects of PDGF-BB (20 ng/ml) on the interaction between b-catenin and HIF-1a in the nucleus in ARCaPM
cells. (D) Confocal microscopy of the effects of PDGF-BB (20 ng/ml) on the co-localization of b-catenin and HIF-1a in the nucleus in ARCaPM cells.
doi:10.1371/journal.pone.0030764.g005
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shown), suggesting that CREB may not be involved in the b-
catenin-dependent activation of Mcl-1 transcription. Intriguingly,
the transcription factor HIF-1a was found to be rapidly increased
in the nucleus and physically interact with b-catenin following
PDGF-BB stimulation, which may mediate Mcl-1 transcription by
binding to HRE site(s) within the promoter. These data are
consistent with a previous study showing that b-catenin can switch
its binding partner from TCF4 to HIF-1a and enhance HIF-1a-
mediated transcription, and this dynamic reassembly of b-catenin
with HIF-1a may allow colorectal cancer cells to rapidly adapt to
hypoxic stress and survive [44]. It is important to note that unlike
the cited work, our studies were performed in normoxic PCa cell
cultures. Since ARCaP cells substantially express HIF-1a even
under normoxia [25], PDGF may significantly affect the
expression of hypoxia-responsive or HRE-containing genes by
promoting the interaction between b-catenin and HIF-1a in a
Wnt-independent mechanism. Upregulation of Mcl-1, as a
consequence, could provide pivotal protection against apoptotic
signals during dissemination and colonization when the majority
of cancer cells remain under normoxia.
Earlier studies reported high expression of PDGFRs in both
localized and metastatic PCa, which could be detected in 88% of
primary tumors and 80% of the metastases [10,45]. However, it
remains controversial as to which PDGFR isoforms are expressed
in PCa cells and primarily responsible for autocrine PDGF
signaling [12,46,47]. These conflicting results may partially arise
from the potential non-specificity of antibodies used in the cited
studies, but more importantly, may reflect the intrinsic heteroge-
neity of human cancers, especially when at their late-stages. In this
study, we were able to detect the expression of both PDGFR
isoforms in several established PCa cell lines by RT-PCR and
Western blot analyses. Given the fact that both PDGFR-a and -b
have been implicated in the progression of bone metastatic PCa
[10,12,13,45,48], our study focused on the function of PDGF-BB
since it is the only PDGF isoform that binds all the three receptor
dimeric combinations (PDGFR-aa,- bb and -ab) with high affinity
[2,49]. To determine which PDGFR isoform is required for PDGF
regulation of Mcl-1, we transfected PCa cells with specific siRNAs
against PDGFR-a or -b. Interestingly, the single depletion of
neither PDGFR-a nor PDGFR-b inhibited Mcl-1 expression in
ARCaPM cells, suggesting that the PDGF-BB signal could be
transduced via the two independent but complementary receptors
to activate Mcl-1 expression in PCa cells expressing both isoforms.
Supporting this notion, dual depletion of both receptors
simultaneously using a mixture of siRNAs against PDGFR-a
and -b effectively inhibited Mcl-1 expression. Alternatively,
treatment with AG-17 or imatinib, two pan-PDGFR inhibitors
that could inhibit the tyrosine kinase activity of both PDGFR-a
and -b, also reduced Mcl-1 levels in ARCaPM cells (Supplemental
Figure 6. A putative HRE site is required for PDGF-BB activation of Mcl-1 promoter. (A) The effects of PDGF-BB on the HIF-1 reporter
activity in ARCaPM cells. The cells were transiently transfected with HIF-1 reporter or pGL3 for 24 h, serum-starved and incubated in the presence or
absence of PDGF-BB (20 ng/ml) for 48 h. (B) Schematic diagram of human Mcl-1 promoter and its deletion mutation at the putative HRE site. (C) The
effects of deleting the putative HRE site on PDGF regulation of Mcl-1 promoter activity in ARCaPM cells. IL-6 (200 ng/ml) was included as the positive
control. (D) ChIP-Re-ChIP assay of the effects of PDGF-BB treatment (20 ng/ml) on the binding of b-catenin and HIF-1a to human Mcl-1 promoter
region in ARCaPM cells.
doi:10.1371/journal.pone.0030764.g006
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one PDGFR isoform (for example, PDGFR-a is the major isoform
in C4-2 cells; Figure 2A, right panel), it is plausible to expect that
inhibition of the isoform alone could affect Mcl-1 expression.
Indeed, transfection of PDGFR-a siRNA in C4-2 cells significantly
inhibited Mcl-1 (Supplemental Figure S6). These findings support
a model that PDGF-BB could activate both PDGFR isoforms in
the regulation of Mcl-1 in PCa cells in a context-dependent
manner, which may have important implication in the evaluation
of PDGFR expression at tissue levels in clinical PCa specimens.
Interaction between PCa and bone microenvironment is crucial
to the bone tropism of PCa metastasis, which is identified at
autopsy in up to 90% of patients dying from the disease [50].
Tumor-initiated bone resorption promotes the release and
activation of multiple growth factors immobilized in bone matrix,
including PDGF. These locally expressed and tumor-derived
PDGF could activate PDGFR signaling in surrounding stroma
(including stromal cells, endothelial cells and pericytes) and
promote angiogenesis. As a potent mitogen for osteoblasts, PDGF
also significantly contribute to the osteoblastic phenotype of PCa
bone metastasis [51]. These effects, taken together, may provide a
favorable microenvironment for the survival and outgrowth of
bone metastatic PCa. These facts provided rationale for evaluating
the potential of treating PCa bone metastasis with small-molecule
PDGFR inhibitors. In earlier studies, imatinib sensitized bone
marrow stromal and endothelial cells to paclitaxel treatment and
significantly suppressed PCa bone metastasis in experimental
models [52,53]. Disappointingly, however, recent clinical trials
with imatinib only achieved limited success due to unexpected
severe side effects in patients [48]. These observations highlighted
the importance of a better understanding of PDGF signaling in
bone metastasis PCa. Our study delineated a novel signaling axis
that may allow PCa cells to escape apoptosis during dissemination
and colonization by activating PDGF-Mcl-1 pathway in metastatic
cancer cells. It is plausible to hypothesize that PDGF-BB may be
crucial in mediating the ‘‘vicious cycle’’ between tumor and bone
microenvironment, not only promoting angiogenesis in surround-
ing stroma but also sustaining survival in PCa cells (Figure 7).
Supporting this model, PDGF-BB was found to be elevated in
PC3-MM2 cells implanted in the mouse bone cortex, and
interestingly, activated PDGFR-b was only detected in tumor
lesions growing adjacent to bone and the tumor-associated
endothelium [53,54]. Given the clinical significance of both
PDGF and Mcl-1 in PCa bone metastasis [21,51], specific
targeting of PDGF-Mcl-1 survival pathway in PCa cells (autocrine
signaling) and co-targeting of microenvironment (paracrine
Figure 7. A proposed model for PDGF-BB regulation of Mcl-1 expression in PCa cells. The engagement of PDGF-BB to PDGFR dimers
activates the c-Abl-p68 cascade, which subsequently stablizes b-catenin and promotes its nuclear translocation. In the nucleus, interaction between
b-catenin and HIF-1a increases the binding of HIF-1a to the HRE site within Mcl-1 promoter, thereby activating the transcription of Mcl-1 gene.
Upregulation of Mcl-1 antagonizes apoptotic signals and confers survival advantages to metastatic PCa cells. Furthermore, tumor-derived and locally
expressed PDGF may mediate the interactions between PCa and bone microenvironment. Co-targeting the PDGF signaling in PCa cells (autocrine)
and microenvironment (paracrine) could provide a new strategy to disrupt the ‘‘vicious cycle’’ and efficaciously treat metastatic PCa.
doi:10.1371/journal.pone.0030764.g007
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and efficaciously treat metastatic PCa.
Supporting Information
Figure S1 The effects of PDGF-BB on the expression of Mcl-
1a tm R N Aa n dp r o t e i nl e v e l si nP C ac e l l s .(A–C) RT-PCR and
qRT-PCR analyses of the time- and dose-dependent effects of PDGF-
BB on Mcl-1 mRNA expression in ARCaPE (A), LNCaP (B) and C4-2
( C )c e l l s .T h ed o s ew a s2 0n g / m li nt h et i m ec o u r s ee x p e r i m e n t s .( D )
Western blot analysis of the effects of PDGF isoforms on the expression
of Mcl-1 in several PCa cell lines. Treatment: 20 ng/ml, 72 h.
(TIF)
Figure S2 The effects of deleting the putative HRE site
on PDGF regulation of Mcl-1 promoter activity in C4-2
cells. IL-6 (200 ng/ml) was included as the positive control.
(TIF)
Figure S3 The effects of p68 siRNA on the expression of
cleaved PARP, an indicator of apoptosis in PCa cells.
ARCaPM cells were transfected with p68 or control siRNA (30
nM) for 48 h, serum-starved overnight, and incubated in the
presence or absence of PDGF-BB (20 ng/ml) for 72 h.
(TIF)
FigureS4 TheeffectofPDGF-BBontheAkt-GSK-3bcascade
in PCa cells. PDGF-BB treatment (20 ng/ml) in ARCaPM cells
increased the phosphorylation of Akt and GSK-b at serine residues.
(TIF)
Figure S5 Imatinib, a small-molecule inhibitor of
PDGFR signaling, inhibits Mcl-1 protein expression in
PCa cells. ARCaPM cells were treated with 10 mM imatinib for
varying times, western blotting was then performed.
(TIF)
Figure S6 Depletion of PDGFR-a abrogates PDGF-BB
induction of Mcl-1 in C4-2 cells. The cells were transfected
with PDGFR-a or control siRNA (30 nM) for 48 h, serum-starved
overnight, and incubated in the presence or absence of PDGF-BB
(20 ng/ml) for 72 h.
(TIF)
Table S1 Antibodies used in this study.
(PDF)
Table S2 Primers for PCR and RT-PCR.
(PDF)
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